Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial
Keywords:
CAR T cell therapy
Idecabtagene vicleucel
Patient experience
Patient-reported outcomes
Relapsed or refractory multiple myeloma
Triple-class exposed
Note:
This is an open access article under the CC BY-NC-ND license
Citation:
Delforge, M.; Rodríguez-Otero, P. (Paula); Shah, N.; et al. "Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial". Leukemia Research. 129, 2023, 107074
Statistics and impact
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.